Bioalliance Submits Fentanyl Lauriad Clinical Trial Application To French Drug Agency

BioAlliance Pharma SA has submitted the clinical trial application for Fentanyl Lauriad to the French Drug Agency (AFSSaPS). The company seeks the approval of this test by the Committee Protection of Persons.

Patented until 2030, Fentanyl Lauriad is based on the same muco-adhesive technology already validated with Loramyc.

Reportedly, the phase I clinical trial will recruit its first subjects before the end of 2009. Fentanyl Lauriad is intended for the treatment of cancer chronic pain.

BioAlliance is a French specialty biopharmaceutical company that develops and markets products in the fields of opportunistic infections, cancer, AIDS and the complications of chemotherapy.